Rationale: Electronic cigarettes (ECs) are becoming popular alternatives for smokers, but there has been limited study of their abuse liability.
Objectives: The objective of this study was to evaluate the abuse liability of three Vuse Solo ECs, ranging from 14 to 36 mg in nicotine content, relative to high- and low-abuse liability comparator products (usual brand combustible cigarettes and nicotine gum, respectively) in a group of 45 EC-naïve smokers.
Methods: Enrolled subjects' ratings of subjective effects and nicotine uptake over 6 h were used to measure abuse liability and pharmacokinetics following in-clinic use of each EC.
Results: Use of Vuse Solo resulted in subjective measures and nicotine uptake that were between those of combustible cigarettes and nicotine gum, although generally closer to nicotine gum. Compared to combustible cigarettes, use of Vuse Solo resulted in significantly lower scores in measures of product liking, positive effects, and intent to use again. These pharmacodynamic findings were consistent with the pharmacokinetic data, showing that cigarettes produced substantially faster and higher levels of nicotine uptake as compared to Vuse Solo and nicotine gum. Vuse Solo resulted in more rapid initial uptake of nicotine compared to nicotine gum, but peak concentration and long-term extent of uptake were not different or were lower with Vuse.
Conclusions: Collectively, these findings suggest that Vuse Solo likely has an abuse liability that is somewhat greater than nicotine gum but lower than cigarettes.
Trial Registration: ClinicalTrials.gov identifier: NCT02269514.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548902 | PMC |
| http://dx.doi.org/10.1007/s00213-017-4665-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
International Expert Consensus on Relevant Health and Functioning Concepts to Assess in Users of Tobacco and Nicotine Products: Delphi Study.
JMIR Form Res
January 2025
PMI R&D, Philip Morris Product S.A., Neuchâtel, Switzerland.
Background: A Delphi study was conducted to reach a consensus among international clinical and health care experts on the most important health and functioning self-reported concepts when evaluating a switch from smoking cigarettes to using smoke-free tobacco and/or nicotine products (sf-TNPs).
Objective: The aim of this research was to identify concepts considered important to measure when assessing the health and functioning status of users of tobacco and/or nicotine products.
Methods: Experts (n=105), including health care professionals, researchers, and policy makers, from 26 countries with professional experience and knowledge of sf-TNPs completed a 3-round, adapted Delphi panel.
A randomized trial for combination nicotine replacement therapy for smoking cessation among people with HIV in a low-resourced setting.
AIDS
December 2024
School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Objective: The purpose of this study was to evaluate the efficacy of combination nicotine replacement therapy (c-NRT) for smoking cessation among people with HIV (PWH) in South Africa.
Design: We conducted an open label, individually randomized clinical trial.
Methods: Using a two-armed approach, PWH who smoke were randomized to receive either 1) intensive anti-smoking behavioral counseling (BC) or 2) intensive anti-smoking BC plus c-NRT (nicotine patches augmented by nicotine gum).
Article Synopsis
- The report highlights a community health system's implementation of universal screening and treatment pathways for youth vaping over a 4-year period.
- Data included screening rates, positive tests, referrals, and quit rates among teens based on their demographics.
- Results showed that 73% of teens were screened, 5.2% tested positive, and among those referred, about 31% achieved vaping abstinence, suggesting this model could effectively help other health systems combat teen vaping.
Appeal and Sensory Characteristics of Oral Nicotine Products in Young Adults Who Vape E-Cigarettes.
Nicotine Tob Res
November 2024
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California.
Introduction: This study applied a novel tobacco regulatory science paradigm to characterize inter-product variation in the appeal and sensory features of emerging commercial and therapeutic oral nicotine products (ONPs) among young adults that vape e-cigarettes.
Methods: Twenty-three young adults without ONP experience who use e-cigarettes completed a single-blind, single-visit remote lab study. Participants rated appeal and sensory characteristics during 5-minute standardized self-administrations of 8 ONPs (4 fruit, 4 mint) from various brands (Lucy, Rouge, Solace, Nicorette, On!, Velo).
Characterization of the nicotine uptake and safety of Nordic spirit tobacco-free oral nicotine pouches: A randomized cross-over study.
Psychopharmacology (Berl)
November 2024
JT International (JTI) SA, 8 Rue Kazem Radjavi, 1202, Geneva, Switzerland.
Article Synopsis
- The study investigates the scientific evaluation of Nordic Spirit nicotine pouches, focusing on their unique composition and how they compare to traditional tobacco products.
- Researchers assessed the blood nicotine delivery, pharmacokinetics, subjective effects, and safety of three different strengths of Nordic Spirit pouches against low-dose tobacco snus and Nicorette gum.
- Results showed that Nordic Spirit NPs delivered nicotine in a dose-dependent manner without significant safety concerns, suggesting their potential for safe human use and further product development.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!